Brief report

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

Amir T. Fathi,¹ Hossein Sadrzadeh,¹ Darrell R. Borger,¹ Karen K. Ballen,¹ Philip C. Amrein,¹ Eyal C. Attar,¹ Julia Foster,¹ Meghan Burke,¹ Hector U. Lopez,¹ Christina R. Matulis,¹ Katherine M. Edmonds,¹ A. John Iafrate,¹ Kimberly S. Straley,² Katharine E. Yen,² Samuel Agresta,² David P. Schenkein,² Cedric Hill,¹ Ashkan Emadi,³ Donna S. Neuberg,⁴ Richard M. Stone,⁴ and Yi-Bin Chen¹

¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; ²Agios Pharmaceuticals, Cambridge, MA; ³Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD; and ⁴Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Mutations of genes encoding isocitrate dehydrogenase (*IDH1* and *IDH2*) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples from patients with *IDH*-mutant AML contain high levels of the metabolite 2-hydroxyglutarate (2-HG), a product of the altered IDH protein. In this prospective study, we sought to determine whether 2-HG can potentially serve as a noninvasive biomarker of disease burden through serial measurements in patients receiving conventional therapy for newly diagnosed AML. Our data demonstrate that serum, urine, marrow aspirate, and myeloblast 2-HG levels are significantly higher in *IDH*-mutant patients, with a correlation between baseline serum and urine 2-HG levels. Serum and urine 2-HG, along with *IDH1/2*-mutant allele burden in marrow, decreased with response to treatment. 2-HG decrease was more rapid with induction chemotherapy compared with DNA-methyltransferase inhibitor therapy. Our data suggest that serum or urine 2-HG may serve as noninvasive biomarkers of disease activity for *IDH*-mutant AML. (*Blood.* 2012;120(23):4649-4652)

Introduction

Mutations in genes encoding isocitrate dehydrogenase (*IDH1/2*) were recently discovered in acute myeloid leukemia (AML).^{1,2} Their prognostic significance remains under investigation.³⁻⁹

IDH proteins catalyze the oxidative decarboxylation of isocitrate to α -ketoglutarate (α -KG). *IDH* mutations reside in the active site¹⁰ and include missense alterations affecting arginine-132 (R132) in IDH1, and the analogous arginine residue (R172), or one at arginine-140 (R140), in IDH2.^{1-3,5,6,8,11} The altered IDH proteins instead catalyze reduction of α -KG to the metabolite 2-hydroxyglutarate (2-HG).¹² 2-HG is normally present at low levels in cells,¹³ readily interconverted by 2-HG dehydrogenase to α -KG,^{14,15} but *IDH* mutations promote its accumulation in myeloblasts and sera of affected patients.¹⁰

No prior studies have prospectively measured 2-HG in *IDH*mutant AML during treatment. We focused on the utility of 2-HG as a potential biomarker of disease burden and sought to assess the effect of treatment on the trajectory and kinetics of 2-HG levels. To accomplish this, we serially measured serum, urine, marrow aspirate, and myeloblast 2-HG during conventional therapy for newly diagnosed AML.

Methods

Adult patients at Massachusetts General Hospital, eligible for treatment of newly diagnosed AML, as defined by World Health Organization criteria,

were enrolled. Samples were obtained through a protocol approved by our institution, Dana-Farber Harvard Cancer Center, its institutional review board, and the scientific review committees, with the approved protocol number 11-121. Informed consent was obtained per the Declaration of Helsinki.

Serum, urine, and marrow samples were obtained for 2-HG measurement before therapy. Mononuclear cells from blood and marrow aspirate were isolated using density gradient centrifugation with Ficoll-Hypaque (GE Healthcare). 2-HG measurement was performed by Agios Pharmaceuticals, with methods previously described.^{13,16} Serum and myeloblast 2-HG levels were considered elevated if > 1000 ng/mL or 1000 ng/2 × 10⁶ cells, respectively, as per previous reports.¹⁰ In those with elevated baseline 2-HG, serum and urine were serially obtained for 2-HG measurement, at days 7, 14, 30, 60, and relapse. Bone marrow samples were collected at baseline, days 14, day 30, and relapse.

IDH1/2 mutational assays were performed through single-base extension sequencing using the SNaPshot assay (Applied Biosystems) and through direct sequencing using the Sanger method, as previously described.¹⁷ The relative *IDH1/2* mutational burden during treatment was determined using next-generation sequencing as number of wild-type to mutant reads. Briefly, *IDH1/2* exon 4 PCR amplicons were generated using primers containing Ion Torrent adapters and unique barcodes. Samples were normalized through quantitative PCR quantification and combined. The resulting library was amplified on Ion Sphere particles by emulsion PCR, and sequencing was performed on the Ion PGM Sequencer (Life Technologies).

AML therapies included cytarabine- and idarubicin-based induction, the DNA-methyltransferase inhibitors decitabine or 5-azacitidine, or low-dose

Submitted June 25, 2012; accepted October 5, 2012. Prepublished online as *Blood* First Edition paper, October 16, 2012; DOI 10.1182/blood-2012-06-438267.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2012 by The American Society of Hematology



Figure 1. 2-HG levels in IDH-mutant and IDH-wild-type samples. 2-HG measurements in samples from patients with a wild-type-*IDH1/2* (n = 33) versus those harboring *IDH1/2*-mutations (n = 9), obtained at presentation, showing 2-HG measurement in serum (A), urine (B), myeloblasts (C), and marrow aspirate (D). Each point represents an individual patient sample; blue dots represent *IDH*-wild-type samples; and red dots, *IDH*-mutant samples. The left column in each figure represents the wild-type samples; and the right column, the mutant samples. In each column, horizontal bars represent the median; and vertical lines, the lower and upper quartiles. (A,C) Dotted line across graphs indicates 2HG levels of 1000 ng/mL serum or 1000 ng/2 × 10⁶ within cells, respectively, above which 2-HG levels were deemed to be elevated in this study. All figures describe a statistically significant difference in 2-HG levels between *IDH1/2*-mutant samples relative to wild-type samples (P < .05). One *IDH*-mutant patient did not have elevated baseline.

cytarabine. Statistical evaluation was performed using a 2-tailed Mann-Whitney test for comparing values between groups and a correlation coefficient to assess relationship between variables.

Results and discussion

Forty-two patients were enrolled, with 10 (24%, 90% exact binomial CI, 14%-37%) displaying baseline elevations in serum or myeloblast 2-HG (supplemental Table 1, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). In 9 of 10 patients, *IDH1/2* mutations were discovered: 2 *IDH1*-R132H, 1 *IDH2*-R172M, and 6 *IDH2*-R140Q mutations. In the remaining patient in whom *IDH* mutations were not found, myeloblast 2-HG was elevated (4040 ng/2 × 10⁶ cells), but serum 2-HG was not (241 ng/mL). No *IDH* mutations were found in 32 patients without elevated 2-HG. One *IDH*-mutant patient did not have elevated serum 2-HG but did demonstrate elevated myeloblast levels.

Serum 2-HG for *IDH*-mutant patients (median, 1863 ng/mL; range, 365.1-66 207 ng/mL) was significantly higher than for *IDH*-wild-type patients (median, 87 ng/mL; range, below quantitative limit [BQL]-755 ng/mL, P < .001; Figure 1A). Urine 2-HG was higher in *IDH*-mutant patients (median, 34 100 ng/mL; range, 8620-282 000 ng/mL vs median, 5525 ng/mL; range, BQL-38 800 ng/mL, P < .001), as were marrow aspirate 2-HG (mean, 27 925 ng/mL vs mean, 924 ng/mL, P < .001), and myeloblast 2-HG (median, 22 880 ng/2 × 10⁶ cells; range, 5560-96 400 ng/ 2 × 10⁶ cells vs median, 148.5 ng/2 × 10⁶ cells; range, BQL-4040 ng/2 × 10⁶ cells, P < .001; Figure 1B-1D). Baseline serum 2-HG was correlated with urine 2-HG levels (r = 0.82, P < .001). We also measured serum 2-HG on 7 samples from healthy persons, all measuring < 100 ng/mL (median, 91 ng/mL; range, 33-93 ng/mL).

In those with elevated baseline 2-HG, serum and urine 2-HG decreased during therapy, concordantly with decreases in blast counts. Seven patients were treated with induction chemotherapy, 2 with 5-azacitidine, and 1 with decitabine. Serum and urine 2-HG levels during treatment are demonstrated for patients who achieved remission after induction (Figure 2A-B). More rapid and profound decreases were noted with induction chemotherapy versus DNA-methyltransferase inhibitor therapy. For the latter, a slower decrease in 2-HG occurred with response, as demonstrated in a patient with partial response to 5-azacitidine, with a follow-up of ~ 250 days (Figure 2G-H).

For 3 patients, marrow samples were available for *IDH* mutational analysis at remission, after induction chemotherapy. Using the SNaPshot assay and/or direct sequencing of loci, an *IDH1/2* mutation was no longer detectable in 2 samples; but in the remaining sample, an *IDH1* R132H mutation was detectable, even with low serum 2HG levels. Interestingly, to date, this is the only



Figure 2. Serial measurement of 2-HG during therapy. Serum (A) and urine (B) 2-HG levels measured serially over the course of the first 60 days of treatment for patients with baseline elevations in 2-HG and who achieved complete remission after induction chemotherapy. (C) *IDH1/2*-mutant allele burden measured serially in marrow samples over the course of the first 30 days of treatment for 3 of these patients with complete remission after induction chemotherapy. (D-F) Serum (D) and urine (E) 2-HG levels measured serially over time for a patient (patient 1 in panels A-C) who received cytarabine- and idarubicin-based induction, went on to relapse at \sim day 150, and was then treated with reinduction therapy consisting of mitoxantrone, etoposide, and cytarabine (MEC), to which he responded transiently before displaying refractory disease. (F) *IDH1*-mutant allele burden for the same patient, measured serially in marrow samples, displaying initial decrease in *IDH1*-mutant allele burden with remission, with subsequent increase associated with relapse. (G-H) Serum (G) and urine (H) 2-HG levels measured serially over time (\sim 250 days) for a patient who received hypomethylating therapy with 5-azacitidine 75 mg/m² intravenously on days 1-5 of 28-day cycles.

patient who has relapsed, at ~ 150 days after induction. His 2-HG increased precipitously with relapse, and again transiently decreased after reinduction, to which he was ultimately refractory (Figure 2D-E). Intriguingly, this patient's baseline serum and urine 2-HG were the highest measured, 66 207 ng/mL and 282 000 ng/mL, respectively. Through next-generation sequencing of available serial samples from 3 patients who received induction therapy, we also found that *IDH1/2* mutational burden (mutant allele as fraction of total *IDH1/2*) decreased over time concordantly with 2-HG (Figure 2C). The mutational burden reached 0%, 1%, and 4%, at remission in these patients, with the latter patient identified as the sole relapser in whom the mutant burden subsequently rose in concordance with 2-HG (Figure 2F).

Emerging evidence suggests that 2-HG plays a role in promoting malignancy.^{10,18,19} 2-HG, structurally homologous to α -KG, may interfere with α -KG–activated enzymes, like TET, histone demethylases, and prolyl hydroxylases, suggesting roles in epigenetic modulation and HIF-1 α down-regulation.^{10,19-22} Reports of aberrant hypermethylation and inactivation of loci in *IDH*-mutant AML are intriguing,²³ with the underlying mechanism possibly related to α -KG down-regulation or increase in 2-HG.²³⁻²⁵

With this study, we provide the first prospective evidence that elevated serum and myeloblast 2-HG are specific features of *IDH1/2*-mutant AML. None of the studied patients with nonelevated 2-HG demonstrated any *IDH* mutations, and 9 of 10 with elevations did have elevated serum or myeloblast 2-HG, suggesting that 2-HG is a discriminatory marker in this setting. The sole sample that demonstrated elevated myeloblast 2-HG, but no *IDH* mutation, is under investigation to determine the underlying cause. We also report that urine and marrow aspirate 2-HG are similarly elevated in *IDH*-mutant patients. Most significantly, our data suggest that serum and urine 2-HG may serve as easily measured, noninvasive biomarkers of disease and can be followed during treatment in patients with elevated baseline levels.

Serum and urine 2-HG decreased with response to therapy in a consistent and predictable fashion. Decreases occurred more rapidly with induction chemotherapy than with DNA-methyltransferase inhibitor therapy, as expected given the kinetics of response to these agents. In all evaluated patients with a baseline elevation in serum 2-HG and who subsequently achieved a complete remission, serum 2-HG decreased to < 500 ng/mL by day 30 and < 200 ng/mL by day 60. We also found that the relative burden of *IDH1/2*-mutant alleles correspondingly decreased with treatment, and this too may serve as a molecular surrogate for disease activity, especially at remission.

Longer follow-up with larger populations will validate the value of 2-HG as a biomarker in monitoring minimal residual disease and predicting clinically meaningful outcomes. In time, 2-HG levels may play an important role in the noninvasive management of patients receiving conventional or IDH-targeted therapy.

Acknowledgments

The authors thank Drs Thomas Spitzer and Ronald Takvorian at the Massachusetts General Hospital Cancer Center for their kind support of this study.

This work was supported in part by the Rogers Family Foundation in Boston, MA (philanthropic grant) and the Massachusetts General Hospital Cancer Center (Thematic Priority #3 Grant).

Authorship

Contribution: A.T.F. developed the study design, performed data collection, management, and analysis, and wrote the manuscript; H.S. performed data collection and analysis and helped create

References

- Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med.* 2009;361(11): 1058-1066.
- Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell*. 2010;17(3):225-234.
- Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the acute leukemia French association group. *J Clin Oncol.* 2010; 28(23):3717-3723.
- Green CL, Evans CM, Hills RK, Burnett AK, Linch1 DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ ITD status. *Blood*. 2010;116(15):2779-2782.
- Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348-2355.
- Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
- Schnittger S, Haferlach C, Alpermann T, et al. IDH mutations can be detected in 28.7% of all normal karyotype AML and have unfavorable impact on the NPM1+/FLT3-ITD⁻ genotype [abstract]. Blood (ASH Annual Meeting Abstracts). 2010:116; Abstract 102.

- Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. *Blood.* 2010; 116(25):5486-5496.
- Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med.* 2012; 366(12):1079-1089.
- Gross S, Cairns RA, Minden MD, et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339-344.
- Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. *Blood*. 2010;116(12):2122-2126.
- Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8): 765-773.
- Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*. 2009;462(7274):739-744.
- Kranendijk M, Struys EA, Salomons GS, van der Knaap MS, Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. *J Inherit Metab Dis.* 2012;35(4):571-587.
- Van Schaftingen E, Rzem R, Veiga-da-Cunha M. L:-2-Hydroxyglutaric aciduria, a disorder of metabolite repair. *J Inherit Metab Dis.* 2009;32(2): 135-142.
- Lu W, Kimball E, Rabinowitz JD. A high-performance liquid chromatography-tandem mass spectrometry method for quantitation of nitrogen-containing intra-

figures; K.K.B., P.C.A., and E.C.A. contributed to the study design and patient enrollment and helped edit the manuscript; J.F. enrolled and monitored patients on study and helped with sample and data collection; M.B. and K.M.E. helped with sample and data collection; D.R.B., H.U.L., C.R.M., and A.J.I. performed mutational analysis for patients on study; K.S.S., K.E.Y., S.A., and D.P.S. helped in the performing and reporting of 2-HG assays at Agios Pharmaceuticals, Cambridge, MA, in kind collaboration; C.H. provided sample processing; A.E. provided figures and helped edit the manuscript; D.S.N. helped with study design, provided biostatistical support, and helped edit the manuscript; R.M.S. helped with study design and helped edit the manuscript; and Y.-B.C. helped with study design and development and edited the manuscript.

Conflict-of-interest disclosure: K.S.S., K.E.Y., S.A, and D.P.S. are employees of Agios Pharmaceuticals. R.M.S. is a consultant for Agios Pharmaceuticals. D.R.B. is a paid consultant for Bio-Reference Laboratories Inc (licensee of SNaPshot). The remaining authors declare no competing financial interests.

Correspondence: Amir T. Fathi, Massachusetts General Hospital, Harvard Medical School, Zero Emerson Place, Suite 118, Boston, MA 02114; e-mail: afathi@partners.org.

cellular metabolites. JAm Soc Mass Spectrom. 2006;17(1):37-50.

- Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncologist*. 2012; 17(1):72-79.
- Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. *Cancer Cell*. 2010;17(3):215-216.
- Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. *J Natl Cancer Inst.* 2010;102(13):932-941.
- Frezza C, Tennant DA, Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. *Cancer Cell.* 2010;17(1):7-9.
- Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep.* 2011;12(5): 463-469.
- 22. Emadi A. At the crossroads: tumor metabolism and epigenetics. *Sci Transl Med.* 2011;3(82): ec68.
- Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010;18(6):553-567.
- Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature*. 2010; 466(7310):1129-1133.
- Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science*. 2009;324(5929):930-935.